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It is widely accepted that metastasis is a late event in cancer progression. Here, however, we show that tumor
cells can disseminate systemically from earliest epithelial alterations in HER-2 and PyMT transgenic mice
and from ductal carcinoma in situ in women. Wild-type mice transplanted with single premalignant HER-2
transgenic glands displayed disseminated tumor cells and micrometastasis in bone marrow and lungs.
The number of disseminated cancer cells and their karyotypic abnormalities were similar for small and large
tumors in patients and mouse models. When activated by bone marrow transplantation into wild-type recipients,
80 early-disseminated cancer cells sufficed to induce lethal carcinosis. Therefore, release from dormancy
of early-disseminated cancer cells may frequently account for metachronous metastasis.INTRODUCTION
The final step in cancer progression is metastasis, according to
the prevailing view based on several clinical and experimental
observations. First, most cancer patients die from metastases
and not from their primary disease. Second, early surgery is often
the only cure. Third, somatic genetic changes accumulate during
local progression (Fearon and Vogelstein, 1990), which was
extrapolated to systemic progression since only rare variant cells
within the tumor gave rise to metastases (Fidler and Kripke,
1977). Fourth, repeated rounds of in vivo selection led to cell
lines with increased metastasis formation (Kang et al., 2003;
Minn et al., 2005). However, several clinical and experimental
observations are inconsistent with this model. For example, me-58 Cancer Cell 13, 58–68, January 2008 ª2008 Elsevier Inc.tastasis can develop from small cancers or even in the absence
of detectable primary tumors (so-called ‘‘cancer of unknown
primary,’’ which ranks among the 10 most frequent cancer diag-
noses) (van de Wouw et al., 2002). Furthermore, epidemiological
analysis of more than 12,000 breast cancer patients indicated
that metastasis might be initiated already 5–7 years before diag-
nosis of the primary tumor (Engel et al., 2003), suggesting that
cancer cells capable to metastasize do not necessarily develop
within large tumors. Also, the notion of early metastasis is indi-
rectly supported by gene expression studies (van’t Veer et al.,
2002), revealing that patients with poor prognosis can be identi-
fied before manifestation of metastasis. Thus, while metastatic
spread seems to be somehow genetically predetermined, the
time point of metastatic dissemination is not resolved.SIGNIFICANCE
Patients with large breast cancers are at higher risk to die from metastasis than patients with small tumors. This was thought
to reflect the late onset of metastatic spread. The finding, reported here, that the earliest transformed cells are capable of
dissemination challenges this notion of late-disseminating, fully transformed cells as sole players in metastasis. It empha-
sizes that additional genetic or epigenetic events and release from dormancy are critical for productive metastatic growth of
early-disseminated cancer cells. Larger tumors may, therefore, affect outgrowth of ectopic cancer cells in ways not yet fully
understood. The peculiar nature of disseminated tumor cells—being genetically different from the primary tumor—must be
considered when designing targeted adjuvant therapies, which are increasingly applied to eliminate remnant occult
metastases.
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critical for designing more effective therapies for systemic can-
cer. For example, if metastatic spread occurs late in progression,
inhibitors of invasion should be able to prevent it. This, however,
was not observed in several clinical trials testing inhibitors of
matrix-metalloproteinases (Coussens et al., 2002). If, however,
tumor cell dissemination occurs early, the question needs to
be addressed how tumor cells can survive in a quiescent state
for years at ectopic sites and how tumor dormancy and meta-
static outgrowth are regulated. Last but not least, if disseminated
tumor cells (DTCs) develop parallel to the primary tumor over
a prolonged time, molecular targets on those DTCs need to be
urgently identified.
We previously addressed the issue of early versus late meta-
static spread by analyzing DTCs in bone marrow of breast cancer
patients years before metastatic manifestation (Klein, 2003).
Such cells displayed different and fewer aberrations than their
matched primary tumors, a finding suggestive of early dissemina-
tion (Schmidt-Kittler et al., 2003). Among those DTCs, we identi-
fied cancer cells that spread before onset of chromosomal insta-
bility (Schardt et al., 2005). Though chromosomal instability has
been observed before histological cancer invasion (Chin et al.,
2004), breast cancer cells may still disseminate before they be-
come chromosomally instable and prior to microscopic invasion.
Interestingly, a subpopulation of these karyotypically normal can-
cer cells in bone marrow displayed HER-2 amplification (Schardt
et al., 2005), a marker of particularly aggressive disease (Al-Kur-
aya et al., 2004; Kronqvist et al., 2004). Therefore, we thought to
search for DTCs in a transgenic HER-2 model of breast cancer at
the earliest time point of atypical epithelial transformation. For
direct comparison, we report on findings of DTCs in 600 breast
cancer patients, including patients with in situ carcinomas.
RESULTS
Epithelial Cells Disseminate in the Premalignant Phase
of Murine Breast Cancers
To study tumor progression more closely, we chose BALB/c
mice transgenic for the activated rat HER-2/neu gene (BALB-
NeuT mice) (Di Carlo et al., 1999), a model that mimics progres-
sion and gene expression profiles of human breast cancer
(Astolfi et al., 2005). Females of this strain, which are hemizygous
for the constitutively activated rat HER-2 gene under control of
the MMTV promoter (Muller et al., 1988), develop invasive mam-
mary cancers, while their HER-2 negative siblings (wild-type
BALB/c mice) remain tumor free (Boggio et al., 1998). In BALB-
NeuT females, mammary epithelia start to express the oncogene
at the onset of puberty (weeks 3 to 4 of age) when the mice be-
come responsive to steroid sex hormones. Epithelial hyperplasia
can be detected microscopically in the mammary glands at
weeks 7–9 (Di Carlo et al., 1999). Progress to in situ carcinomas
occurs between weeks 14 and 18. Around week 18 tumors of the
mammary glands become palpable or visible, and at weeks
23–30, invasive cancers become apparent (Figure 1A). Mice
have to be euthanized between weeks 27 and 33 when primary
tumors exceed the size of 1.5 cm in diameter and lung metasta-
ses are macroscopically detectable.
The principal goal of the study was to find out when cells
expressing the HER-2 transgene disseminate and how theyemigrate from the dysplastic breast epithelia. Since the HER-2
receptor is expressed neither in normal lung tissue nor in bone
marrow, we concentrated on these organs as preferred sites of
metastasis in breast cancer patients. In addition, for the detec-
tion of early human cancer spread in bone marrow, staining with
anti-cytokeratin (CK) antibodies is specific and sensitive as dem-
onstrated by numerous studies (Braun et al., 2005; Klein, 2003),
including simultaneous staining with anti-CK and anti-CD45
panhematopoietic antibodies, which showed CD45-negativity
of the cells (Schlimok et al., 1987). Surprisingly, in BALB-NeuT
mice, cytokeratin positive (CK+) cells and HER-2 expressing
cells (HER-2+) became detectable in bone marrow at as early
as 4–9 weeks of age when the most meticulous analysis of the
mammary gland could detect areas of atypical ductal hyper-
plasia (ADH) solely (Figure 1C and Figures S1A–S1C available
with this article online). In lung tissue, single HER-2+ tumor cells
became detectable from week 9 on, and micrometastases were
first visible around week 20 (Table S1 and Figure 1B). Further-
more, the descent of lung micrometastases from mammary tis-
sue was confirmed by the demonstration of mammary-specific
alpha casein and lactalbumin transcripts (Figure 1B). The spec-
ificity of tumor cell detection by antibodies directed against
HER-2 and cytokeratin was further controlled using samples of
nontransgenic siblings (Figure 1C).
Despite exponential growth at the primary sites (which is
depicted as sum of the total tumor area of the ten mammary
glands of BALB-NeuT mice in Figure 1C), the number of CK+
and HER2+ cells in bone marrow rose marginally over the course
of time (4/500,000 to 17/500,000 and 1/500,000 to 7/500,000,
respectively; Figure 1C). As the total number of cells singly
positive for HER-2 and CK were not congruent, we performed
double staining for the two antigens. Indeed, not all tumor cells
expressed both markers (Figure 1D), suggesting either the
existence of heterogeneous tumor cell populations that disse-
minated to distant sites or different cellular states of the disse-
minated tumor cells (DTCs). Interestingly, the majority of all
detected DTCs (n = 35 cells in 7 mice) were CK+ (71%), while HER-2
was expressed in less than 50%. Similar data were obtained
from blood samples (Table S2), although the detection rate of
DTCs was lower than in bone marrow.
To test whether early dissemination is only characteristic for
BALB-NeuT mice, we also screened bone marrow samples
from MMTV-polyomavirus-middle T transgenic mice (Maglione
et al., 2001). Though we were unable to establish immunohisto-
logical detection of tumor cells by antibodies directed against
the PyMT antigen, tumor cells were detected at weeks 4–6 in
bone marrow by anti-CK staining (Figures S2C and S2D) when
only ADH or DCIS was found in mammary tissues (Figure S2A).
Lung micrometastases, although difficult to detect by hematox-
ylin/eosin (HE) staining alone, were found starting from 14 weeks
of age (Figure S2B). As in the BALB-NeuT mice, we observed no
significant increase in numbers of DTCs in bone marrow during
tumor growth (Table S3).
Tumor Cells Emigrate from Transgenic Mammary
Gland Transplants in Wild-Type Siblings
Although cytokeratin expression in bone marrow provided
strong evidence that the cells were indeed derived from epithe-
lia, we sought direct evidence that the HER-2+ and CK+ cellsCancer Cell 13, 58–68, January 2008 ª2008 Elsevier Inc. 59
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Disease in BALB-NeuT
(A) Left panel: Whole mount of the mammary gland
of a BALB-neuT mouse at week 9 showing the ab-
sence of tumor in the branching ductal tree. ‘‘N’’
indicates lymph node, arrow points to the nipple,
and arrowheads show side buds into and around
the mammary ducts. Middle panel: Histological
section of mammary gland at week 9 showing
that side buds display the morphology of atypical
ductal hyperplasia (ADH) with epithelial cells ar-
ranged in small, well-defined nodules around the
duct. Right panel: Histology of invasive cancer in
week 30. The neoplastic epithelial cells form pseu-
doalveolar and scarcely defined solid nests invad-
ing the surrounding fibroadipose stroma.
(B) Left panel: Detection of micrometastases by
anti-HER-2 antibodies in lung of a 27 week-old
mouse. Right panel: Eight HER-2+ (micro)meta-
stasis in the lungs from three transgenic mice
(week 27) and two samples of normal lung tissue
were microdissected and analyzed for the mam-
mary-gland-specific transcripts lactalbumin and
alpha-casein. ‘‘+’’, microdissected tissue of nor-
mal mammary gland; ‘‘’’, mock-control.
(C) Progression of local and systemic disease in
BALB-neuT mice over time. Left panel: Increase
of tumor area (triangles indicate mean values,
whiskers 95% confidence interval with solid line
between triangle indicating best fitted curve).
Right panel: number of CK+ (red dots) and HER-2+
(blue dots) cells per 500000 bone marrow cells
(whiskers indicate 95% confidence interval,
dashed red or blue line depicts results from non-
transgenic control mice for CK or HER-2, respec-
tively).
(D) Immunofluorescent double staining of bone
marrow cells for CK (red) and HER-2 (green)
expression. Left to right: CK+/HER-2 small two-
cell-aggregate; CK/HER-2+ single cell; CK+/
HER-2+ small aggregate (3 cells). Table summa-
rizes the results of all analyzed cells.had disseminated from the transformed breast tissue and that
the detection of positive cells was not due to extramammary
transgene expression. Therefore, we transplanted mammary
gland fragments from 3- to 12-week-old transgenic mice (n = 8)
orthotopically onto 3-week-old wild-type siblings (n = 16). Each
recipient received in one cleared fat pad one tissue fragment
of one donor gland. Bone marrow of the recipients was then
screened for CK+ and HER-2+ cells 7–26 weeks later. In all recip-
ients of BALB-NeuT mice transplants, we found the HER-2 trans-
gene to be expressed in the grafts at dissection (Figure 2A).
In transplanted wild-type animals, the number of CK+ or HER-
2+ cells per 500,000 bone marrow cells (Figures 2B and 2C) was
lower than in BALB-NeuT mice (p < 0.0001 and p = 0.002,
respectively; Mann-Whitney-test; Figure 2D) but significantly
above very rare false-positive cell numbers in control mice (on
average 4 in 107 bone marrow cells for CK and 6 in 107 for
HER-2; p < 0.0001 for CK+ and HER-2+ cells, Mann-Whitney-
test; Figure 2D). Most likely this reflects the reduced total number
of transgenic mammary cells in recipient mice carrying a single
transgenic gland compared to BALB-NeuT mice carrying ten
transgenic mammary glands. In the transgenic mice, we had60 Cancer Cell 13, 58–68, January 2008 ª2008 Elsevier Inc.analyzed the histology of the largest tumor only, ignoring the
remaining 9 mammary glands, while in transplant recipient
mice, we scrutinized the single tumor arising from the transgenic
mammary graft for signs of invasiveness; the exact staging of the
transplant was based on histology after complete serial section-
ing. Again, no increase of DTCs in bone marrow was observed
from the stage of ADH on up to the stage of invasive cancer
(p = 0.26 for CK+ cells and p = 0.83 for HER-2+ cells; Mann-Whit-
ney-test; Figure 2E). The malignant origin of the CK+ or HER-2+
disseminated cells detected in bone marrow was established by
single-cell comparative genomic hybridization (CGH) (Klein et al.,
1999). Both CK+ and HER-2+ cells isolated from bone marrow
displayed multiple chromosomal aberrations in contrast to single
leukocytes with normal CGH profiles (Figure 2F and Figure S3).
Thus, CGH ascertained the malignancy of the cells, which unambi-
guously originated from the single transplanted mammary glands.
Gene Expression Programs Associated
with Early Tumor Spread
In the BALB-NeuT and the PyMT tumor models, dissemination
begins shortly after expression of the oncogenic transgene
Cancer Cell
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Transformed Mammary Tissue
(A) HER-2 staining of grafted tissue at autopsy 14 weeks after
transplantation of transgenic tissue into wild-type mice. Nu-
merous epithelial cells in the atypical ductal hyperplasia
(ADH) focus express HER-2 (in brown).
(B and C) CK+ and HER-2+ cells in bone marrow of recipient
wild-type mouse, respectively.
(D) Box plot displaying numbers of CK+ and HER-2+ cells per
500,000 bone marrow cells of BALB-NeuT, wild-type Balb/c
mice, and wild-type recipients of transplanted transgenic
mammary tissue (transplant).
(E) Box plot displaying numbers of CK+ and HER-2+ cells per
500,000 bone marrow cells of wild-type recipients of trans-
planted transgenic mammary tissue. IC, invasive cancer.
(F) Representative results of CGH analysis of isolated single
cells from different models. Only chromosomal regions (desig-
nated according http://www.informatics.jax.org/mgihome/
nomen/anomalies.shtml) with aberrations are shown. Left col-
umn depicts identifiers of the mice with the letters ‘‘C’’ and ‘‘H’’
indicating the antigen used for detection (C, cytokeratin; H,
HER2) (281-9-C9 to 281-9-H6, CK+ and HER-2+ cells isolated
at week 9 from BALB-NeuT mice; 158-29-C31 to 102-27-H1,
CK+ and HER-2+ cells isolated at week 27-29 from BALB-
NeuT mice; MT10-C229 to MT16-H301, CK+ and HER-2+
cells isolated from bone marrow of wild-type mice after mam-
mary tissue transplantation; BMT5-C119 to BMT3-H61, CK+
and HER-2+ cells isolated from bone marrow of wild-type
mice after bone marrow transplantation.)without histologically detectable signs of invasion. By light mi-
croscopy, the underlying basement membrane showed no gross
interruptions. This raised the question of how transformed epi-
thelial cells get out of the atypical hyperplastic areas. However,
when examined by electron microscopy, epithelial cells crossing
the basement membrane were clearly identified (Figures 3B and
3C for BALB-NeuT mice and Figures S2E and S2F for MMTV-
PyMT). In wild-type siblings, neither basement membrane lesions
nor emigrating cells were discerned (Figure 3A). The observation
that the basement membrane underlying hyperplastic epithelia
appeared to be disrupted in BALB-NeuT mice begged the ques-
tion whether a local activation of proteolytic enzymes could be
verified there. We, therefore, applied cDNA array analysis of laser
microdissected samples to assess the expression of invasion-
associated proteases in ADH at week 9 and large carcinomas
at week 27 using a recently established mRNA amplification
method (Klein et al., 2002a, 2002b) and hybridized the samples
onto a small, dedicated cDNA array (Figure 3D). This array com-
prised 41 cDNAs encoding matrix-metalloproteases (MMPs) and
cathepsins that have earlier been implied in invasion and metas-
tasis (Egeblad and Werb, 2002; Turk et al., 2002). A higher
expression of cathepsins Ctsz, Ctsb, Ctsf, Ctsl, Ctsd, and Ctsh;
metalloproteases Mmp2, Mmp14, Mmp11, and Timp3; and
caspases Casp2 and Casp9 was observed in the early lesions
(false discovery rate q = 4.7% for week 9 compared to
week 27). The increases in Ctsz (p = 0.0046), Ctsd (p = 0.0046),
Mmp2 (p = 0.009), Ctsh (p = 0.0132), and Ctsb (p = 0.0215)expression were significant in a one-sided Wilcoxon test (cor-
rected according to Hochberg). The gene expression patterns
at week 9 could be separated from those at week 27 by cluster
analysis (cluster robustness index = 0.901; Figure 3D), except
for a few outliers. For Mmp2, we found by immunohistochemistry
that the protein is not expressed in normal tissue of young mice
(week 9, Figure 3E) while strongly expressed in ADH at week 9
in transgenic mice (Figure 3F).
Abundant protease expression in hyperplastic lesions may
provide a mechanism for early tumor spread and may be part
of a gene regulatory program. We, therefore, determined the
expression of the transcription factor Twist, which is a morpho-
genetic regulator affecting cell migration, a marker of undifferen-
tiated mammary cells, and apparently plays a role in metastasis
by regulating both cell invasion and intravasation (Howe et al.,
2003; Yang et al., 2004). We compared mRNA expression from
several glands from wild-type mice (n = 10), lesions with ADH
(n = 16), and areas of invasive cancers dissected from central
parts (n = 19) or the invasion front (n = 12) by quantitative PCR.
More than 90% of samples from normal mammary glands,
central tumor areas, and microdissected areas from the invasion
front displayed no or very low levels of Twist mRNA. In contrast,
ADH lesions expressed Twist mRNA significantly more often at
medium or high levels (p = 0.02, Pearson Chi-square, df = 6,
two-sided; Figure 3G), which is in keeping with the notion that
the genetic program governing cell dissemination is activated
during early transformation.Cancer Cell 13, 58–68, January 2008 ª2008 Elsevier Inc. 61
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Mammary Tissue and Activation of Invasive
Properties during ADH
(A–C) Electron microscopical analyses of mammary
tissue. (A) Mammary duct of a 9-week-old wild-type
sibling BALB/c mouse lined by polygonal large dark
and light cells with luminal microvilli and dark myoepi-
thelial cells (M) located at the basal surface without lu-
minal contact. Throughout, the duct is surrounded by
a well-defined basal membrane (arrowheads), which
continuously outlines the basal borders of the epithe-
lial and myoepithelial cells. (B and C) Mammary duct of
a 9-week-old BALB-NeuT mouse lined by polygonal,
irregularly arranged cells. (B) Indifferent small- and
medium-sized cells without luminal contact frequently
show aspects of stromal invasiveness disrupting the
basal membrane. Myoepithelial cells are scarcely
present. (C) Higher magnification of the cell-disrupting
basal membrane (arrowheads, intact basal mem-
brane; arrows, disrupted basal membrane).
(D) Cluster analysis of expression data from the cDNA
array dedicated to molecules from the proteolytic sys-
tem. Sample identifiers on the right consist of age in
weeks, the number of the mouse from which the sam-
ple was taken, and the sample number; individual
samples from one animal were isolated from different
mammary glands. Note clustering of samples from 9-
week-old mice in the lower third of the figure display-
ing upregulation of various proteolytic enzymes.
(E and F) Immunohistochemistry with anti-MMP2 anti-
body showing scarce MMP2 expression in wild-type
BALB/c mice at 9 weeks of age (E), while strong ex-
pression (in brown) in side buds and ducts with ADH
of 9-week-old BALB-NeuT mice (F).
(G) Quantitative RT-PCR of Twist mRNA. Microdis-
sected tissue samples isolated from transgenic ani-
mals at week 9 (ADH) and 27 (tumor edge and center)
and wild-type BALB/c-mice (normal). Asterisks indi-
cate significant upregulation of Twist in ADH samples.Evidence that Early-Disseminated Cells Grow
into Metastases
The intriguing finding of tumor cells disseminating from preinva-
sive mammary lesions raised the question of whether they also
may grow into metastases. Although the time point of dissemina-
tion of metastatic founder cells cannot be determined directly
in vivo, we obtained evidence of early systemic spread of founder
cells from the following different types of experiments.
We assessed the onset of metastasis relative to primary tumor
growth. Histological sections of the lungs were therefore taken to
detect the presence of micrometastases and to measure their
increase over time (Figure 4B). These could be detected from
weeks 20 to 21 onward, a time point at which mostly in situ
carcinomas are present at the primary sites (Figure 4A). Since
metastases need time to grow, their increase in size paralleling
that of the primary lesions supports the conclusion that, at least
in some cases, founder cells of metastases had disseminated
there earlier and had started to proliferate.
To address this point more directly we performed surgery on
BALB-NeuT mice and tried to remove the entire milk line. Only
mice older than 18 weeks survived this radical procedure. How-
ever, for none of the four 18-week-old mice displaying in situ62 Cancer Cell 13, 58–68, January 2008 ª2008 Elsevier Inc.carcinomas only, we could prevent or reduce the number or
size of lung metastases at 27–33 weeks of age (Figure 4B).
To test whether DTCs from large tumors differ from early-
disseminated tumor cells, we compared their chromosomal ab-
errations. We reasoned that, while dissemination occurs early,
only genetically further-progressed cancer cells would be able
to grow into metastases. We, therefore, analyzed the CGH
profiles from tumor cells isolated from bone marrow of mice at
week 9 and older than week 27 by hierarchical cluster analysis
and support-vector-machine classification (Figure S4). We could
not separate the tumor cells from young and old animals and
could not detect a significant increase of aberrations from young
to old animals (p = 0.3485, exact Wilcoxon rank sum test).
A final set of experiments was directed at tumor progression
in wild-type females that had received orthotopic grafts of mam-
mary glands from their 3- to 4-week-old transgenic siblings. In
these mice, lung (micro)metastases became detectable at about
40 weeks of age while BALB-NeuT females with autochthonous
primary cancers developed lung metastases at 30 weeks on av-
erage (Figure 4B). Next, we excised the engrafted glands again
at various time points and followed the operated recipients. In
recipients (n = 8) from which the grafted glands had been excised
Cancer Cell
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Balb-NeuT Mice and Wild-Type Recipients
of Transgenic Mammary Tissue
(A and B) Progression of lung metastasis in BALB-
NeuT mice with and without removal of primary tu-
mors. Increase of tumor area over time ([A], same
as Figure 1C) is plotted next to the sizes of the larg-
est lung metastases (note logarithmic scale) de-
tected in individual mice (B). Blue squares indicate
average size of metastases from nonoperated
mice at various time points, red triangles indicate
the average size of metastases from operated an-
imals at 10–15 weeks after surgery, and whiskers
indicate 95% confidence interval.
(C–H) Tumor progression after transplantation of
noncancerous mammary tissue from BALB-
NeuT mice into wild-type siblings. (C and D)
Histology of graft tissue at surgery 26 weeks after
transplantation resembling ADH (C) and small in-
vasive carcinoma (D). HE- (E) and HER-2 staining
(F) of lung micrometastasis 13 weeks after sur-
gery. (G) Experimental design to assess tumor
progression in wild-type recipients of mammary
glands after surgery. Primary tumors were ana-
lyzed after 26 weeks in euthanized and operated
mice. Asterisks indicate time points when lung
and bone marrow samples were analyzed. (H) Re-
sults of transplantation experiments of mice treated with curative intention by surgery (ADH, atypical ductal hyperplasia; IC, invasive carcinoma). Note the small
size of resected tumors when compared to tumors of BALB-NeuT mice in (A) and the unusually high number of HER2-positive cells in BM of MT1 diagnosed
with ADH.23–26 weeks after primary transplantation, the mammary tissue
was diagnosed with atypical ductal hyperplasia (ADH) in two
recipients (Figure 4C), with small invasive cancers of < 9 mm2
in four recipients (Figure 4D), and with invasive cancers measur-
ing between 30–35 mm2 in the remaining two recipients (tallying
with tumors of BALB-NeuT females before week 18 and at week 22,
respectively; Figure 4A). After an additional 11–13 weeks, the
operated recipients were sacrificed and screened for local relapse
and for tumor cells in bone marrow and lungs (Figure 4G). In none
of the animals did we observe a local relapse, but all displayed
signs of either minimal residual disease or lung metastasis.
Even animals with very small primary lesions in the resected
glands carried HER-2+ micrometastasis in their lungs (Figures
4C–4F). We then compared the incidence of lung (micro)meta-
stases between animals that had been diagnosed with invasive
cancer and either sacrificed (n = 10) or operated (n = 6) about
26 weeks after mammary tissue transplantation (Figure 4G). Of
the 10 animals that were sacrificed at this time point, only one
mouse harbored lung micrometastasis. In contrast, of the six
animals with resection of the transplanted mammary tissue by
surgery at week 26, four of them were diagnosed with metastatic
growths (micrometastasis or metastases) in the lungs 11–13
weeks later (p = 0.036; Fisher’s exact test, Figures 4G and 4H).
This finding indicates that disseminated cancer cells continued
to progress and underscores that the single case with ADH
and lung micrometastasis indeed represents progressive mini-
mal residual disease (Figure 4H).
Early DTCs Can Be Released from Growth Arrest
Obviously, tumor cell dissemination occurs early but additional
mechanisms regulate outgrowth. For example, at no time point
could we observe manifest bone metastasis or a frequency oftumor cells of more than 104 in bone marrow of BALB-NeuT
mice. Therefore,weaskedwhether DTCs inbonemarrowofyoung
mice could proliferate and generate progeny after stimulation with
endogenousgrowth factors and chemokines as a consequence of
irradiation. We transplanted bone marrow from transgenic mice
into lethally irradiated nontransgenic siblings. Three transgenic
donors (11 weeks old) were euthanized, and 7 to 10 3 106 bone
marrow cells were transplanted i.v. into 11 wild-type littermates
(Figure 5). The bone marrow of one wild-type BALB/c mouse
was transplanted into three siblings as control. Staining with CK
antibodies revealed the presence of 4–12 positive cells per 0.53
106 bone marrow cells in the inoculum of transgenic mice, indi-
cating a total of 80–240 CK+ cells per recipient mouse. Nineteen
to 22 weeks later, all bone marrow transplant recipients became
moribund (four animals were found dead before their bone mar-
row could be analyzed), and autopsy showed massive infiltration
of bone marrow by CK+ cells comprising 10%–31% of all nucle-
ated cells (Figures 5A and 5B). Irradiated mice receiving bone
marrow from wild-type BALB/c siblings (n = 3) were healthy until
they were sacrificed (weeks 19, 28, and 43, respectively) and har-
bored no CK+ cells in their bone marrow. So far, all isolated single
CK+ and HER-2+ cells from recipient animals displayed CGH
abnormalities, demonstrating their malignant origin (Figure 2G).
Interestingly, no metastases were detected at other sites. The ex-
periments demonstrate that bone-marrow-derived tumor cells
disseminated during ADH and can establish bone marrow carci-
nosis upon transplantation.
Dissemination of Tumor Cells Is Not Associated
with Tumor Size in Human Breast Cancer
One provocative finding of our study is that, in mouse models of
breast cancer, large tumors seed neither more nor geneticallyCancer Cell 13, 58–68, January 2008 ª2008 Elsevier Inc. 63
Cancer Cell
Systemic Spread Is an Early Step in Breast CancerFigure 5. DTCs from 11-Week-Old Transgenic Mice Form Bone Marrow Carcinosis in Wild-Type Recipients
(A) Bone marrow sample full of CK+ cells (dark blue-black cells) indicating bone marrow carcinosis.
(B) Summary of bone marrow transplantation experiments from HER-2 transgenic or control mice into wild-type sibling BALB/c mice.further-advanced cancer cells than do small lesions (Figure 1C
and Figure S4, respectively). Thus, the ability of metastatic dis-
semination does not appear to be the result of selection of tumor
cells within the tumor. Rather, the data suggest that tumor cells
disseminate early and will be selected for outgrowth at distant
sites. We analyzed samples from breast cancer patients to test
this hypothesis. From 607 breast cancer patients, we screened
bone marrow samples for the presence of DTCs and assessed
the number of DTCs for the different sizes of primary tumors.
We found no association between the tumor stage and the
presence of disseminated cells (p = 0.38, Pearson’s chi-square,
df = 6, two-sided; Figure 6A) and specifically, the finding of CK+
cells in patients with ductal carcinoma in situ (DCIS; 13%)
and T1-stage patients (22%) was statistically not different
(p = 0.093, Pearson’s chi-square test). However, the number of
CK+ cells seeded to bone marrow in DCIS patients is signifi-
cantly higher than observed in control patients (Braun et al.,
2000), which were stained using the same antibody (mab A45
B/B3; p = 0.001, Pearson’s chi-square test, 2-sided).
Finally, as in the BALB-NeuT model, we ruled out that tumor
cells in bone marrow of patients with large primary tumors are
Figure 6. Number and Karyotype of DTCs Detected in Bone Marrow
of Breast Cancer Patients
(A) Number of detected CK+ cells per 2 3 106 bone marrow cells in patients
with different tumor stages (DCIS, n = 39; T1, n = 328; T2, n = 202; and
T3/4, n = 38).
(B) Karyotypes of CK+ cells in bone marrow of breast cancer patients. Patients
harboring DTCs with only normal, with only abnormal, and with normal and ab-
normal karyotypes are not differentially distributed between tumor stages. (T1,
27 patients with 49 DTC; T2, 23 patients with 39 DTC; and T3/4, 6 patients with
17 DTC).64 Cancer Cell 13, 58–68, January 2008 ª2008 Elsevier Inc.genetically further advanced than disseminated cancer cells of
patients with small tumors. We had previously shown that
bone marrow samples of breast cancer patients contain CK+ tu-
mor cells without chromosomal aberrations, while the matched
primary tumors displayed abnormal karyotypes (Schardt et al.,
2005). Such cells apparently disseminated before the onset of
chromosomal instability at the primary site, which is thought to
occur before stroma invasion (Chin et al., 2004). Furthermore,
the malignant origin of cytokeratin-positive cells with normal
karyotypes was established by demonstration of loss of hetero-
zygosity (Schardt et al., 2005). We concluded that such cells
represent the earliest stages of genetic tumor development. In
following up this lead, we examined the chromosomal aberra-
tions of DTCs in bone marrow taken from patients in various
tumor stages. Patients were classified into those harboring
only cells with CGH abnormalities, only cells without CGH abnor-
malities, and those harboring both types of tumor cells in bone
marrow. We analyzed 105 single cells isolated from 56 patients
and could not observe a significant difference between patients
with small and large cancers (Figure 6B; p = 0.17, Pearson’s chi-
square, df = 4), indicating that the well-known association of
large tumor size and development of manifest metastasis is
not explained by an increased frequency of genetically pro-
gressed cancer cells in bone marrow.
DISCUSSION
Here, we provide evidence that dissemination of tumor cells in
mouse models of breast cancer as well as in the human disease
can occur in preinvasive stages of tumor progression and that
the number and genotype of seeded tumor cells is not associ-
ated with tumor size. Both findings should modify the prevailing
view that metastatic dissemination is a late event and that the
association of tumor size and risk for metastasis reflects a higher
frequency of tumor cell seeding. Implicit in this view is the
surmise that extended periods of genetic progression within
the primary tumor are required for metastatic dissemination,
which our findings do not support. Chromosomal aberrations
in DTCs—either of the BALB-neuT mouse model or of human
breast cancers—are not associated with increased tumor size
though they accumulate over time in human cancer as amply
shown by Mitelman and Heim (Heim and Mitelman, 1995).
Mouse models and human samples, therefore, concurred on
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the primary lesion, dissemination is highest early after transfor-
mation.
Interestingly, in the BALB-NeuT model, activation of the
proteolytic system in breast epithelia was associated with young
age and ADH. Moreover, a quantitative analysis of Twist expres-
sion, comparing lesions with ADH, central and peripheral regions
of a large tumor, and normal samples, revealed a significant
upregulation in early-transformed breast cancer cells, exceeding
even expression levels of the so-called invasion front of the
primary tumor. Twist expression has been associated with epi-
thelial-mesenchymal transition, migration, invasion, and cell-
cycle deregulation (Stasinopoulos et al., 2005; Yang et al.,
2004). The activation of a specific genetic program early after
sex-hormone-induced expression of the transforming oncogene
HER-2 may, thus, initiate microinvasion, which can be detected
by transmission electron microscopy in breast lesions as early as
in the stage of ADH. These lesions are defined as noninvasive,
and no evidence of invasion was detected after careful light-
microscopic inspection by an experienced pathologist (P.M.).
Yet, both the BALB-NeuT and the PyMT mice harbored HER+
DTCs in lung and bone marrow and CK+ cells in bone marrow
during ADH. Evidence for their malignant origin was provided
by comparative genomic hybridization. An ectopic transgene ex-
pression at these sites could be excluded by the transplantation
experiments where mammary grafts grew on wild-type back-
ground. Also here, epithelial cells disseminated to bone marrow
and lungs at the stage of ADH and displayed genetic aberrations.
The existence of a genetic program associated with dissemina-
tion but only transiently activated in early lesions might explain
why in human breast cancer Twist expression was rarely found
in invasive ductal carcinomas (Yang et al., 2004).
We performed several experiments to assess whether in
mouse models, early-disseminated cancer cells may give rise
to metastasis. First, growth of metastasis occurs during transi-
tion of primary lesions from noninvasive to invasive, which indi-
cates that tumor cells had disseminated much earlier and started
to grow at the distant site. Second, at week 18, when only in situ
carcinomas were present, resection of the glands neither
prevented nor reduced the number of lung metastases. Third,
dissemination and early lung colonization were found also in
wild-type females that had only transiently carried a single trans-
genic mammary graft. At resection, most grafts displayed only
very small invasive cancers. In one of two cases where the trans-
plant was surgically removed at the stage of ADH, the cells had
started to form metastatic colonies when analyzed 10–13 weeks
after surgery. Thus, while the number of experiments is currently
too low to quantify the frequency of manifest metastasis as
consequence of ADH, it is safe to state that early-disseminated
tumor cells occasionally have metastatic potential. However,
we noted that the course of the disease in the transplanted
wild-type siblings was prolonged as compared to the transgenic
animals with autochthonous tumors. While in BALB-neuT fe-
males metastases are regularly present at week 30, in wild-
type mice (micro)metastases appeared only more than 40 weeks
after transplantation of a transgenic gland. At least two possibil-
ities may account for this observation: Although we transplanted
the mammary tissue before expression of the transgene into re-
cipient mice, which should result into peripheral immunologicaltolerance, we cannot exclude that immunosurveillance against
the rat transgene product slowed down systemic cancer pro-
gression. Alternatively, surgical removal of the primary lesions
at very early time points may deprive early-disseminated cancer
cells from systemically acting factors important for outgrowth.
Such factors secreted from the primary tumor may prepare the
metastatic niche and foster early cancerous colonies as recently
suggested (Kaplan et al., 2005). Thus, large primary breast can-
cers in patients may support metastasis not by seeding more
cancer cells, but by providing unknown systemically acting
factors that stimulate colonization of previously disseminated
tumor cells at the ectopic site. This reasoning is backed by find-
ings that patients with small (T1-stage) tumors harbor similar
numbers of disseminated cancer cells as patients with late stage
tumors (T3 to T4) present in our cohort of 607 patients. In a meta-
analysis of several studies on DTCs in breast cancer, employing,
however, rather different techniques for DTC detection but total-
ing more than 4700 patients, Braun and coworkers observed an
increase of positive bone marrow samples from 22% in stage
T1 to 34% in stage T3 (Braun et al., 2005). These data give further
support to the conclusions that large tumors in relation to small
tumors seed far less tumor cells to bone marrow: On average,
primary T3 tumors comprise about 350 times more cancer cells
than T1-stage tumors, but the percentage of patients with DTCs
in bone marrow increases only marginally. Thus, the poorer
prognosis of patients with T3-stage breast cancers cannot be
explained by increased DTC numbers, but so far unknown exter-
nal triggers may be responsible for metastatic outgrowth that
currently are rather underestimated. In this context, it is notewor-
thy that while the highest number of DTC in bone marrow during
the lifetime of BALB-neuT mice never exceeds 104 bone mar-
row cells, transplantation of transgenic bone marrow containing
a total of about 80 tumor cells per inoculum taken from 11-week-
old BALB-neuT mice and injected into irradiated wild-type
animals resulted in bone marrow carcinosis with more than
30% of all cells being of cancerous origin. Since the donor
bone marrow had been taken from mice with ADH, this suggests
that the tumor cells may be released from dormancy or some
type of quiescence—possibly as consequence of the stimulatory
microenvironment during repopulation of the irradiated bone
marrow compartment—and eventually grow out.
Though the finding of microinvasion at the stage of ADH may
not apply to all patients with breast cancer, the detection itself
of disseminated cancer cells in DCIS suggests that conventional
histopathological analysis may miss tumor spread in human can-
cer as well. Although very rare, metastasis in DCIS patients has
been observed despite complete resection of their mammary tis-
sue (Cutuli et al., 2001). Other well-known clinical findings, such
as cancer of unknown primary (van de Wouw et al., 2002) as well
as inadvertent transfer of cancer with organ transplants from do-
nors with small undiagnosed malignant lesions (Riethmuller and
Klein, 2001), are equally consistent with early dissemination and
potential metastatic outgrowth.
Taken together, our findings suggest a concept of cancer
progression according to which metastatic dissemination is
a distinct early step in cancer progression being necessary,
but not sufficient, for metastatic outgrowth. The interactions of
early-disseminated cancer cells with their ectopic microenviron-
ment leading to selection or adaptation within an early metastaticCancer Cell 13, 58–68, January 2008 ª2008 Elsevier Inc. 65
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perimental approaches than the frequent use of cell lines derived
from late stage tumors. Previous work and the present work
demonstrate that essential steps of genetic progression take
place at the ectopic site and not within the primary tumor. The
understanding of which mechanisms promote the outgrowth of
DTCs often after extended periods of cancer latency might be
key to the prevention of the lethal metastases.
EXPERIMENTAL PROCEDURES
Mice
BALB-NeuT and MMTV-PyMT mice transgenic mice were maintained in our
facilities according the European Union guidelines. All animal experiments
were performed according to the EU and national institutional regulations.
Mice were screened at 3 to 4 weeks of age for hemizygosity (neuT+/neuT),
and negative littermates served as wild-type BALB/c mice controls. Mammary
glands of BALB-NeuT female mice were inspected twice a week and arising
tumors were measured with calipers in two perpendicular diameters (Boggio
et al., 1998). Tissue samples from transgenic MMTV-PyMT mice (FVB strain)
were obtained from Christoph Peters and Thomas Reinheckel (Institute for
Molecular Medicine, University of Freiburg).
Bone Marrow Preparation
After sterile preparation of both femurs, bone marrow was rinsed with a 26-G
needle in 1 ml of PBS. After density gradient centrifugation, 53 105 interphase
cells were dropped on adhesion slides (Menzel, Germany). At least 106 cells per
mouse were stained, and positive cells were isolated using a micromanipulator.
Immunostaining
For the detection of disseminated cells, anti-CK 8 and 18 (GP11, Progen,
Germany) and anti-HER-2 (c-erbB2, Dianova, Germany) antibodies were
used in a concentration of 5 mg/ml and visualized by ABC complex/AP
(Dako, Denmark) using the AP substrate BCIP/NBT (Biorad, Germany). For
HER-2 immunohistochemistry of solid tissues, 5 mm cryosections of primary
tumors or lung tissue were stained. For MMP2 immunohistochemistry, formal-
dehyde-fixed tissues were embedded in paraffin wax. Rabbit polyclonal anti-
MMP-2 (Chemicon International, AB809) was applied in a 1:250 dilution.
Laser Microdissection, DNA, and mRNA Preparation
Laser microdissection, single-cell isolation, and nucleic acid preparation for
DNA and mRNA was performed as described previously (Klein et al., 2002a,
2002b; Schmidt-Kittler et al., 2003). Small pieces summing up to 100,000 mm2
for each sample were catapulted into a cap with 6 ml PCR oil and centrifuged
into a 200 ml reaction tube (for DNA) while for mRNA analysis the tissues were
catapulted into reaction tubes containing 10 ml paramagnetic oligo-dT bead
suspension and lysis buffer (Dynal).
Quantitative PCR
Real-time PCR was performed using a LightCycler (Roche) and Fast Start
Master SYBR Green Kits (Roche). Analysis was done using the RelQuant soft-
ware (Roche) with PCR efficiency normalization and a reference sample in-
cluded in every run. Pooled mRNA from TUBO cells (Curcio et al., 2003) served
as positive control. Measurements showing unspecific products in the melting
curve analysis were discarded from further analysis. All expression levels are
given relative to Gapdh (primer sequences are provided in Table S4).
Comparative Genomic Hybridization, Image Acquisition,
and Analysis
Murine control DNA and tumor DNA were labeled with biotin-16-dUTP and
digoxigenin-12- dUTP (Roche Germany), respectively, and detected after hy-
bridization to metaphase chromosomes using anti-DIG-FITC Fab Fragments
(200 mg/ml, Roche, Germany) and biotinylated normal DNA by avidin-Cy 3.5
(Rockland, USA). Images were recorded by a Leica DMXA-RF8 microscope
(Leica acquisition program QFISH) equipped with a Sensys CCD camera66 Cancer Cell 13, 58–68, January 2008 ª2008 Elsevier Inc.(Photometrics, USA). Processing and karyotyping was done using the Leica
software package Q-CGH.
Array Hybridization and Analysis
After global mRNA amplification, PCR-amplified cDNA fragments were digox-
igenin labeled and nonradioactively hybridized to nylon filters (Klein et al.,
2002a). Scanning and significance analysis (SAM) was performed as published
(Tusher et al., 2001; Zohlnhofer et al., 2001). The clustering of proteases was
done for the Euclidean distances, complete linkage for proteases, and average
linkage for cases. Cluster assessment was performed using BRB ArrayTools
developed by Dr. Richard Simon and Amy Peng (McShane et al., 2002).
Calculation of Tumor Progression over Time
Tumor areas were calculated from 407 mammary glands of 41 mice assuming
the shape of an ellipse/circle for each tumor. The tumor size/area of a mam-
mary gland without a tumor was set to zero. The curve was fitted using Fried-
man’s scatterplot smoother. HER-2+ cells from 31 samples (28 mice) and CK+
cells from 33 samples (31 mice) were calculated as the sum of single dissem-
inated cells and the number of aggregates. Measurements from similar time
points (± 1 week) were consolidated. An offset of ±0.3 weeks was used to
draw HER-2+ (0.3) and CK+ (+0.3) cells in one plot. The number of CK+
and HER-2+ cells from nontransgenic BALB/c mice were measured in
25 mice (CK) and 24 mice (HER-2) at five time points (weeks 4, 9, 18, 22, and
29) and connected by a dotted line. The area of lung metastases was mea-
sured using the PALM Robo V1.2.3 software and calculated as sum of all
metastases found. Values were averaged over two tissue sections. The size
of metastases was measured from four mice with and 14 mice without surgery,
and measurements from similar time points (± 2 week) were consolidated.
Surgery of Mammary Tumors
Mice were anaesthetized with ketamin 80–120 mg i.p. and xylazin 5 mg i.p
sufficient for 90–120 min. Thorax and abdomen were shaved, skin was incised
from caudal to cranial in the midline, and subcutaneous tissue was prepared,
i.e., the breast glands together with fatty tissue, and resected in toto after
coagulation of vessels. The skin was closed by a suture using prolene, 4-0,
Ethicon, Germany. Surgery took usually 30–60 min and mice were kept under
a warming lamp until awakening. Postoperative analgesia was achieved by
25 mg metamizol every 4 hr p.o. After 8 days, sutures were removed.
Tissue Transplantation
Surgical techniques and the transplantation procedure has been previously
described (Daniel et al., 1968; Deome et al., 1959). Briefly, the nipple region
from the fourth fat pad on the right side of 3-week-old recipient BALB/c
mice was removed under anesthesia. Then, a piece of donor mammary tissue
(approximately 1 to 2 mm in size) from 3- to 12-week-old BALB-neuT mice was
implanted in the ‘‘cleared’’ mammary fat pad of recipient mice.
Bone Marrow Transplantation
Eleven week-old BALB-NeuT mice were euthanized and bone marrow was
harvested from femurs and tibiae. 7-9 X 106 bone marrow cells injected into
the tail vein of 11 week-old lethally irradiated (split dose day –2 and day 0:
550 rad) wild-type siblings. From the remaining bone marrow, slides were
prepared as described above to determine tumor load by CK staining.
Analysis of Breast Cancer Patients
From our previous study on disseminated breast cancer cells, we included all
270 nonmetastatic patients (T1-4, N0-2, M0) for which information on T-stage
was available and four patients with DCIS. Cytokeratin-positive cells were
detected and isolated for genetic analysis, and their DNA was amplified for
comparative genomic hybridization as described before (Schmidt-Kittler
et al., 2003). In addition, 298 breast cancer patients with unilateral primary
breast cancer (T1–T4, N0–N2, M0) and 35 patients with DCIS undergoing
surgery at the Department of Oncology and Obstetrics, University of Tu¨bingen,
Germany, were included. Bone marrow sampling, preparation, staining, and
screening were performed according to the consensus protocol for the detec-
tion of disseminated cancer cells (Fehm et al., 2006) applying the mab A45-B/B3
antibody (Micromet, Germany). All bone marrow samples were taken with
the approval of local ethics committees and after obtaining informed consent
Cancer Cell
Systemic Spread Is an Early Step in Breast Cancerof the patients. Data for the control group of normal individuals, including 191
patients with nonmalignant disease (153 patients with benign lesions of the
breast, such as fibroadenomas, mastitis, abscesses, and cysts; 11 with simple
cysts; 10 with cystadenoma of the ovaries; and 17 with cervical intraepithelial
neoplasms of grade I or II), was taken from the study of Braun et al. (2000).
Supplemental Data
The Supplemental Data include four supplemental figures and four supple-
mental tables and can be found with this article online at http://www.
cancercell.org/cgi/content/full/13/1/58/DC1/.
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